ArticleBlood advances2026

Long-term efficacy and safety of ropeginterferon alfa-2b under its HIDAT regimen for the treatment of polycythemia vera.

Shanshan Suo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.